SCHEMBL1881986

SCHEMBL1881986

Nc1nc(-c2cccc(OCc3cccc(Cl)c3)c2)c2cc(Cl)ccc2n1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DHFR P00374 3/20 0.55
BACE1 P56817 1/20 0.54
SLC9A3 P48764 1/20 0.51
DCPS Q96C86 2/20 0.50
HSP90AB1 P08238 1/20 0.50
ADORA2A P29274 1/20 0.48
IGF1R P08069 1/20 0.48
NR4A2 P43354 1/20 0.46
PKM P14618 1/20 0.46
F9 P00740 1/20 0.45
F10 P00742 1/20 0.45
MAOB P27338 3/20 0.45
EGLN1 Q9GZT9 1/20 0.44
PIN1 Q13526 1/20 0.44
MPO P05164 1/20 0.43
APP P05067 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1877258 0.93 BACE1 (0.52) DHFRBACE1SLC9A3DCPSHSP90AB1
SCHEMBL1879985 0.92 BACE1 (0.55) DHFRBACE1SLC9A3DCPSHSP90AB1
SCHEMBL1879741 0.92 HSP90AB1 (0.55) DHFRBACE1SLC9A3DCPSHSP90AB1
SCHEMBL1880116 0.89 MRGPRX4 (0.56) BACE1NR4A2EGLN1
SCHEMBL1875717 0.89 NR1H2 (0.49) DHFRBACE1SLC9A3HSP90AB1ADORA2A
SCHEMBL1879142 0.89 BACE1 (0.48) DHFRBACE1SLC9A3DCPSHSP90AB1
SCHEMBL1871638 0.89 ADORA2A (0.53) DHFRBACE1SLC9A3DCPSHSP90AB1
SCHEMBL1879323 0.89 BACE1 (0.48) DHFRBACE1SLC9A3DCPSHSP90AB1
SCHEMBL1876600 0.88 HSP90AB1 (0.62) DHFRBACE1SLC9A3DCPSHSP90AB1
SCHEMBL1877697 0.88 BACE1 (0.52) DHFRBACE1SLC9A3DCPSHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US claimed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US claimed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN claimed
EP-1881965-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS Merck Patent GmbH (DE) 2008-01-30 EP claimed
WO-2006122631-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS MERCK PATENT GMBH (DE) 2006-11-23 WO claimed
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US disclosed
CN-101180278-B 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH 2011-05-04 CN disclosed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US disclosed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN disclosed
EP-1881965-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS Merck Patent GmbH (DE) 2008-01-30 EP disclosed
WO-2006122631-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS MERCK PATENT GMBH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators HSP90AB2P, HSP90AB1, HSP90AA1 DHFR 2653/4885BACE1 4518/4885SLC9A3 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.